IPO registrations (S-1, F-1) · Registrants
Vyant Bio, Inc.
- SEC CIK
- 1349929 · filings on EDGAR ↗
- Former names
- CANCER GENETICS, INC (2011–2021); CANCER GENETICS INC (2006–2010)
- Registration
- Form S-1, first filed 2011-12-30, last 2022-04-29; 5 initial registrations, 27 amendments
- Outcome
- Final prospectus filed 2013-04-05; declared effective 2013-04-04; withdrawal requested 2013-03-29
- Industry (SIC)
- Services-Medical Laboratories 8071
- Incorporated in
- DE
- Business address
- 2370 STATE ROUTE 70 WEST, SUITE 310, Cherry Hill,, NJ 08002
- EIN
- 04-3462475
- EDGAR entity type
- operating
- Insiders and CEO pay
- Vyant Bio, Inc. on the corporate pages
Offering terms
- Proposed price range
- $10.00–$12.00 per share (S-1/A filed 2013-04-01)
- Final price
- $10.00 per share, within the range (424B4 filed 2013-04-05, an initial public offering)
- Shares sold
- 600,000
- Gross proceeds
- $6,000,000 before underwriting discounts and any over-allotment option
- Listing
- under the symbol CGIX
- Lead underwriters
- Aegis Capital (420,000 shares)
- Syndicate
- Feltl and Company (180,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CANCER GENETICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: VYANT BIO, INC. EXACT (EIN (EXACT))
- Form D issuer: CANCER GENETICS, INC EXACT (CIK (EXACT))
- SEC filer: CANCER GENETICS, INC EXACT (CIK (EXACT))
Filings 54
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-12-30 | S-1 | S-1 (registration) | CANCER GENETICS, INC | 0001193125-11-356362 ↗ |
| 2012-02-14 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-059565 ↗ |
| 2012-03-13 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-112311 ↗ |
| 2012-04-03 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-146686 ↗ |
| 2012-04-23 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-175594 ↗ |
| 2012-04-30 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-196735 ↗ |
| 2012-05-07 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-213736 ↗ |
| 2012-05-16 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-235838 ↗ |
| 2012-10-23 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-430558 ↗ |
| 2012-11-16 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-472809 ↗ |
| 2012-12-14 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-12-502167 ↗ |
| 2013-01-08 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-006376 ↗ |
| 2013-01-23 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-019562 ↗ |
| 2013-02-08 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-046270 ↗ |
| 2013-02-12 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-050021 ↗ |
| 2013-02-12 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-051961 ↗ |
| 2013-02-14 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-055860 ↗ |
| 2013-03-04 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-088936 ↗ |
| 2013-03-11 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-100617 ↗ |
| 2013-03-22 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-119990 ↗ |
| 2013-03-29 | RW | RW (withdrawal request) | CANCER GENETICS, INC | 0001193125-13-134761 ↗ |
| 2013-04-01 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-136969 ↗ |
| 2013-04-04 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-13-000878 ↗ |
| 2013-04-05 | 424B4 | 424B4 (final prospectus) | CANCER GENETICS, INC | 0001193125-13-144246 ↗ |
| 2013-06-05 | S-1 | S-1 (registration) | CANCER GENETICS, INC | 0001193125-13-248745 ↗ |
| 2013-07-12 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-289434 ↗ |
| 2013-07-25 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-301581 ↗ |
| 2013-08-05 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-318295 ↗ |
| 2013-08-12 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-330064 ↗ |
| 2013-08-13 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-13-002396 ↗ |
| 2013-08-14 | 424B4 | 424B4 (final prospectus) | CANCER GENETICS, INC | 0001193125-13-334651 ↗ |
| 2013-10-08 | S-1 | S-1 (registration) | CANCER GENETICS, INC | 0001193125-13-394340 ↗ |
| 2013-10-17 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-401850 ↗ |
| 2013-10-21 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001193125-13-404751 ↗ |
| 2013-10-22 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-13-003045 ↗ |
| 2013-10-23 | 424B4 | 424B4 (final prospectus) | CANCER GENETICS, INC | 0001193125-13-408121 ↗ |
| 2014-06-05 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-14-001688 ↗ |
| 2016-12-22 | S-1 | S-1 (registration) | CANCER GENETICS, INC | 0001349929-16-000139 ↗ |
| 2017-01-11 | S-1/A | S-1/A (amendment) | CANCER GENETICS, INC | 0001349929-17-000004 ↗ |
| 2017-01-13 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-17-000106 ↗ |
| 2017-06-05 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-17-001456 ↗ |
| 2020-07-21 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-20-001874 ↗ |
| 2021-02-08 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-21-000510 ↗ |
| 2021-02-12 | EFFECT | EFFECT (declared effective) | CANCER GENETICS, INC | 9999999995-21-000629 ↗ |
| 2021-06-04 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-21-002212 ↗ |
| 2022-04-29 | S-1 | S-1 (registration) | Vyant Bio, Inc. | 0001493152-22-011626 ↗ |
| 2022-05-09 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-22-001377 ↗ |
| 2022-05-12 | 424B4 | 424B4 (final prospectus) | Vyant Bio, Inc. | 0001493152-22-012936 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000666 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000667 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000669 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000670 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000671 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | Vyant Bio, Inc. | 9999999995-23-000675 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-04-01 | S-1/A | registration statement | $10.00–$12.00 | $11.00 | 600,000 | $6,600,000 | CGIX | 2 | primary document; range, price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
| 2013-04-05 | 424B4 | final prospectus | $10.00 | 600,000 | $6,000,000 | CGIX | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cannon Edmund | Director | 10 | 2013–2019 | ||
| Chaganti Raju S.K. | Director | 12 | 2013–2019 | ||
| CZEREPAK ELIZABETH | Officer | Chief Financial Officer | 1 | 2013 | |
| El Naggar Jane Houldsworth | Officer | VP of Research and Development | 3 | 2013–2014 | |
| PAPPAJOHN JOHN | Director; Director,TenPercentOwner | 35 | 2013–2019 | ||
| Pecora Andrew L | Director | 4 | 2013 | ||
| PRENDERGAST FRANKLYN G | Director | 9 | 2013–2019 | ||
| SHARMA PANNA | Director,Officer | Chief Executive Officer; President & CEO | 7 | 2013–2017 | |
| Thompson Tommy G | Director | 2 | 2013 | ||
| Brownlie Keith L | Director | 4 | 2013–2014 | ||
| Rothman Paul | Director | 2 | 2014 | ||
| Sitar Edward J | Officer | CFO, Secretary & Treasurer; Chief Financial Officer | 7 | 2014–2016 | |
| Welsh Michael J. | Director | 7 | 2014–2017 | ||
| Harris Geoffrey E. | Director | 19 | 2014–2023 | ||
| McLeod Howard | Director | 10 | 2014–2022 | ||
| Hepburn Steven | Officer; Other | VP of Biopharma Marketing | 4 | 2015 | |
| Shaknovich Rita | Officer | Chief Medical Officer; VP of Hematopathology Services | 3 | 2015–2018 | |
| ROBERTS JOHN A | Director,Officer; Officer | Chief Executive Officer; Chief Operating Officer | 13 | 2016–2022 | |
| Gitelman Igor | Officer | Chief Accounting Officer | 3 | 2017 | |
| Brandt Ralf | Officer | President, Discovery Services | 4 | 2017–2021 | |
| Widmann Thomas F | Director | 1 | 2017 | ||
| McCartney Michael Brian | Officer | Chief Commercial Officer | 2 | 2018 | |
| Miles Michael Glenn | Officer | Chief Financial Officer | 3 | 2018–2020 | |
| Finger William Lansing | Officer | EVP Precision Medicine | 1 | 2019 | |
| Boehm Marcus | Director | 13 | 2021–2022 | ||
| FLETCHER R JOHN | Director | 10 | 2021–2023 | ||
| Hansen Paul R. | Director | 11 | 2021–2023 | ||
| Horobin Joanna | Director | 8 | 2021–2023 | ||
| LaFrence Andrew D.C. | Officer | Chief Financial Officer | 7 | 2021–2022 | |
| Yeh Yung-Ping | Director; Director,Officer | Chief Innovation Officer | 7 | 2021–2022 | |
| Fremeau Robert Thomas Jr. | Officer | Chief Scientific Officer | 3 | 2021–2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-02-03 | CANCER GENETICS, INC | Biotechnology | $10,000,000 | $10,000,000 | 6 | 1 |
| 2017-03-27 | CANCER GENETICS, INC | Biotechnology | $6,000,000 | $6,000,000 | 3 | 1 |
| 2016-12-05 | CANCER GENETICS, INC | Biotechnology | $5,500,000 | $5,500,000 | 16 | 1 |
| 2016-05-25 | CANCER GENETICS, INC | Biotechnology | $5,000,000 | $5,000,000 | 41 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CANCER GENETICS, INC. | NJ | State business registries | EIN (EXACT, as the state registration reports it) |
| Plan sponsor | VYANT BIO, INC. | MN | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | CANCER GENETICS, INC | NJ | Form D private offerings | CIK (EXACT) |
| SEC filer | Vyant Bio, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | VYANT BIO, INC. | NJ | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | VYANT BIO, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Medical Laboratories, NJ first:
- QUEST DIAGNOSTICS INC NJ
- MEDICAL RESOURCES INC /DE/ NJ
- DPD HOLDINGS INC NJ
- IMPATH INC NY
- DYNACARE INC A6
- INSIGHT HEALTH SERVICES CORP CA
- AMERIPATH INC FL
- PRECISION THERAPEUTICS INC PA
- CLARIENT, INC CA
- BIOCEPT INC CA
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Services-Medical Laboratories · Health